Ioversol
Title: Ioversol
CAS Registry Number: 87771-40-2
CAS Name: N,N¢-Bis(2,3-dihydroxypropyl)-5-[(hydroxyacetyl)(2-hydroxyethyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide
Additional Names: N,N¢-bis(2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl)glycolamido]-2,4,6-triiodoisophthalamide
Manufacturers' Codes: MP-328
Trademarks: Optiray (Mallinckrodt)
Molecular Formula: C18H24I3N3O9
Molecular Weight: 807.11
Percent Composition: C 26.79%, H 3.00%, I 47.17%, N 5.21%, O 17.84%
Literature References: Nonionic, low osmolality, radiographic contrast agent. Prepn: Y. Lin, EP 83964; idem, US 4396598 (both 1983 to Mallinckrodt). Clinical pharmacokinetics: R. A. Wilkins et al., Invest. Radiol. 24, 781 (1989). Comparative clinical study in intravenous urography: A. J. Kaufman et al., Urol. Radiol. 12, 56 (1990). Toxicity studies: W. H. Ralston et al., Invest. Radiol. 24, Suppl. 1, S2 (1989). Symposium on pharmacology, toxicology and diagnostic use in contrast enhanced computed tomographic scanning and angiography: ibid. S1-S76.
Properties: mp 186-198°. Soly in water >125% wt/vol. Partition coefficient (octanol/water): 0.0004 (c = 0.01 mgI/ml). Osmolality: 702 mOsm/kg H2O (c = 320 mgI/ml). Viscosity (cP): 11.6 (20°); 9.9 (25°); 5.8 (37°) (c = 320 mgI/kg). d37 1.371 (c = 320 mgI/ml). LD50 in mice, rats, rabbits, dogs (gI/kg): 17, 15, >25, >12 i.v.; in male, female rats (mgI/kg): 1000, >1200 intracisternally (Ralston).
Melting point: mp 186-198°
Log P: Partition coefficient (octanol/water): 0.0004 (c = 0.01 mgI/ml)
Density: d37 1.371 (c = 320 mgI/ml)
Toxicity data: LD50 in mice, rats, rabbits, dogs (gI/kg): 17, 15, >25, >12 i.v.; in male, female rats (mgI/kg): 1000, >1200 intracisternally (Ralston)
Therap-Cat: Diagnostic aid (radiopaque medium).
Keywords: Diagnostic Aid (Radiopaque Medium).

Others monographs:
ChlornitrofenOil of MyrtleCalcium BorogluconateDihydroactinidiolide
Ammonium BenzoateAlmagateFerrous Carbonate MassPurothionin
Isobutyl IsovalerateEpitiostanolAcemannanCalcium Hypochlorite
PlaunotolMethamidophosRoquinimexDrofenine
©2016 DrugLead US FDA&EMEA